Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,679Revenue (TTM) $M1,165Net Margin (%)--Altman Z-Score--
Enterprise Value $M--EPS (TTM) $0.8Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M76.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CBST

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CBSTPrem Watsa 2014-12-31 Buy 0.13%$60.05 - $100.71
($77.67)
$ 101.9431%New holding20,200
CBSTMario Gabelli 2014-12-31 Buy 0.12%$60.05 - $100.71
($77.67)
$ 101.9431%New holding236,700
CBSTFirst Eagle Investment 2014-12-31 Buy $60.05 - $100.71
($77.67)
$ 101.9431%New holding20,000
CBSTKen Fisher 2014-12-31 Reduce$60.05 - $100.71
($77.67)
$ 101.9431%Reduce -93.82%2,150
CBSTVanguard Health Care Fund 2014-09-30 Add0.09%$60.5 - $70.58
($65.63)
$ 101.9455%Add 34.74%1,977,342
CBSTGeorge Soros 2014-06-30 Sold Out -0.04%$61.66 - $74.27
($67.99)
$ 101.9450%Sold Out0
CBSTKen Fisher 2014-06-30 Buy 0.01%$61.66 - $74.27
($67.99)
$ 101.9450%New holding36,450
CBSTGeorge Soros 2014-03-31 Reduce-0.06%$67.2 - $81.23
($74.39)
$ 101.9437%Reduce -65.40%50,000
CBSTJoel Greenblatt 2013-12-31 Sold Out -0.05%$61.59 - $70.76
($64.66)
$ 101.9458%Sold Out0
CBSTMichael Price 2013-09-30 Sold Out -1.2%$51.58 - $66.54
($60.56)
$ 101.9468%Sold Out0
CBSTGeorge Soros 2013-06-30 Buy 0.09%$44.66 - $56.11
($49.15)
$ 101.94107%New holding175,000
CBSTJoel Greenblatt 2013-03-31 Reduce-0.18%$40.78 - $48.06
($44.18)
$ 101.94131%Reduce -72.24%28,134
CBSTJoel Greenblatt 2012-12-31 Buy 0.25%$39.17 - $48.63
($43.07)
$ 101.94137%New holding101,334
CBSTJoel Greenblatt 2012-09-30 Sold Out -0.12%$37.91 - $49.83
($43.89)
$ 101.94132%Sold Out0
CBSTJoel Greenblatt 2012-06-30 Add0.04%$38.38 - $44.07
($40.88)
$ 101.94149%Add 49.02%41,492
CBSTJoel Greenblatt 2012-03-31 Reduce-0.17%$38.77 - $44.72
($38.64)
$ 101.94164%Reduce -55.29%27,844
CBSTGeorge Soros 2012-03-31 Sold Out -0.09%$38.77 - $44.72
($38.64)
$ 101.94164%Sold Out0
CBSTJoel Greenblatt 2011-12-31 Reduce-0.42%$34.05 - $40.38
($37.51)
$ 101.94172%Reduce -53.85%62,273
CBSTGeorge Soros 2011-12-31 Reduce-0.03%$34.05 - $40.38
($37.51)
$ 101.94172%Reduce -50.00%50,000
CBSTMichael Price 2011-09-30 Add0.49%$29.59 - $36.93
($34.13)
$ 101.94199%Add 73.57%182,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBST is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CBST: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-10-01Sell48,125$65.3955.9view
STEA GREGORYSVP, Commercial Operations 2014-08-19Sell38,326$65.8854.74view
Hutson Nancy JDirector 2014-08-18Sell9,000$6556.83view
PEREZ ROBERT JPresident & COO 2014-08-18Sell1,003$63.6860.08view
TOMSICEK MICHAEL JOHNSVP & CFO 2014-08-18Sell409$63.6860.08view
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-07-28Sell40,625$61.5765.57view
STEA GREGORYSVP, Commercial Operations 2014-05-15Sell875$67.551.02view
PEREZ ROBERT JPresident & COO 2014-05-15Sell1,518$67.551.02view
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-05-15Sell16,340$67.8250.31view
BONNEY MICHAEL WCEO 2014-05-15Sell3,036$67.551.02view

Quarterly/Annual Reports about CBST:

    News about CBST:

    Articles On GuruFocus.com
    Mario Gabelli's Top 5 Stock Picks Mar 30 2015 
    Prem Watsa Buys 2 and Sells 1 Stock in Fourth Quarter Feb 16 2015 
    Mario Gabelli's Top 5 New Stock Buys of Q4 Feb 05 2015 
    Gabelli's Q4 Picks Include Acquisition Targets Feb 06 2015 
    Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
    Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
    Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
    Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
    5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 

    More From Other Websites
    FDA approves Cubists' drug for antibiotic-resistant bacteria Dec 19 2014
    Cubist sales force seen as potential boon for Merck intestinal drug Dec 10 2014
    Cubist sales force seen as potential boon for Merck intestinal drug Dec 09 2014
    Merck committed to Cubist after patent losses Dec 09 2014
    Merck says still plans Cubist purchase, despite patent setback Dec 09 2014
    After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired? Dec 09 2014
    Merck dives into 'superbug' chase with Cubist Dec 08 2014
    Merck to buy Cubist Pharmaceuticals for $8.4 billion Dec 08 2014
    Court rules Hospira can launch generic Cubicin in 2016 Dec 08 2014
    US STOCKS-Wall St falls with energy shares; global data disappoints Dec 08 2014
    Cubist options unusually active before Merck deal Dec 08 2014
    US STOCKS-Wall St flat after Japan, China data; biotechs climb Dec 08 2014
    US STOCKS-Wall St slips after Japan, China data; energy drags Dec 08 2014
    US STOCKS-Wall St to open lower after Japan, China data Dec 08 2014
    Merck, Cubist Agree to $9.5 Billion Acquisition Dec 08 2014
    US STOCKS-Futures lower after China, Japan data disappoints Dec 08 2014
    US STOCKS-Futures fall after soft China, Japan data Dec 08 2014
    Merck buying Cubist Pharmaceuticals for $8.4B Dec 08 2014
    Merck takes aim at superbugs, to buy Cubist in $9.5 bln deal Dec 08 2014
    PRESS DIGEST- Financial Times - Dec 8 Dec 07 2014

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)